Role of Tumor Associated Fibroblasts in Human Liver Regeneration, Cirrhosis, and Cancer

Table 2

Surface immunophenotype of N-, C-, and L-MASCs. Bonferroni post test: *𝑃<0.05 C- versus L-MASCs; **𝑃<0.05 N- versus L-MASCs.

		MASCs		P
	N	C	L
CD49b	99.3 ± 1.6	98.4 ± 4.1	84 ± 14	0,0008^*, **
CD13	98.6 ± 2.8	97.8 ± 5.4	97 ± 7	n.s.
CD73	97 ± 5.7	98.3 ± 2.9	93 ± 10	n.s.
CD44	90 ± 21.84	92.2 ± 14.5	91 ± 17	n.s.
CD90	90.6 ± 16.4	92.2 ± 19.5	79 ± 20	n.s.
CD59	89.2 ± 23.8	98.2 ± 4.1	82 ± 9	n.s.
CD29	88.5 ± 15.4	91.1 ± 19.4	79 ± 15	n.s.
CD49a	86 ± 33.3	89 ± 10.3	70 ± 9	n.s.
CD105	84.6 ± 12.9	86.3 ± 21.5	75 ± 16	n.s.
CD49d	54.9 ± 43.7	46.2 ± 31.6	98 ± 2	0.008*
E-cadherin	4.39 ± 7.5	3.75 ± 9	n.d.
CD10	37.7 ± 28.8	31.1 ± 33.4	8.2 ± 10.9	n.s.
N-cadherin	2.56 ± 5.3	2.15 ± 5.1	n.d.
CD66e	0.41 ± 0.58	0.24 ± 0.51	1.4 ± 1.7	n.s.
CD271	0.22 ± 0.20	0.39 ± 0.65	0.52 ± 0.16	n.s.
CD45	0.19 ± 0.26	0.16 ± 0.35	0.05 ± 0.04	n.s.
ABCG2	0.18 ± 0.10	0.24 ± 0.2	0.21 ± 0.12	n.s.
CD117	0.17 ± 0.23	0.11 ± 0.15	0.03 ± 0.05	n.s.
CD133	0.17 ± 0.19	0.23 ± 0.27	0.18 ± 0.24	n.s.
CD34	0.11 ± 0.10	0.10 ± 0.18	0.03 ± 0.05	n.s.